A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...

Indian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...

The company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...

Adani Energy Solutions Limited is acquiring IntelliSmart Infrastructure Private Limited for Rs 3,050 crore. This deal will create India's l...

India's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin ...

Despite geopolitical turmoil and inflation, domestic consumption of essentials and personal care products remains resilient. Company execut...

The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...

Zydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The tota...

Investors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...

Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...

Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...

In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...